SOLY - Soliton: A Smart Acquisition Even As It Spoils Price Action Potential
- Soliton just announced a definitive agreement to be sold to Allergan Aesthetics, an AbbVie company, for $22.60 a share, valuing the company roughly 100% higher than my initial investment initiation.
- The acquisition is a smart move for AbbVie, which will get their hands on Soliton's recently approved RESONIC tech and enjoy the market growth potential.
- It's a smart move for Soliton as well, as they now gain access to the company's distribution and marketing infrastructure. Even so, it's a spoiler for potential price action growth.
For further details see:
Soliton: A Smart Acquisition, Even As It Spoils Price Action Potential